| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer (NCT06570031) | Ono Pharmaceutical Co., Ltd. | 2021-11-09 |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (NCT04360941) | Royal Marsden NHS Foundation Trust | 2020-08-11 |
| B002 in Patients With HER2-positive Breast Cancer (NCT04382352) | Shanghai Pharmaceuticals Holding Co., Ltd | 2019-05-28 |
| ModraDoc006/r in Patients With Breast Cancer (NCT03890744) | Modra Pharmaceuticals | 2019-01-30 |
| T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (NCT03530696) | University of Arizona | 2018-12-06 |
| Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (NCT03750396) | Gangnam Severance Hospital | 2018-08-01 |
| Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing (NCT03475979) | Seoul National University Hospital | 2018-05-01 |
| Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer (NCT02843126) | Fuda Cancer Hospital, Guangzhou | 2016-07-01 |
| 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer (NCT02624700) | Virginia Commonwealth University | 2016-01-28 |
| Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer (NCT02203552) | Ohio State University Comprehensive Cancer Center | 2015-06-23 |
| Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer (NCT02390427) | Otto Metzger, MD | 2015-04-20 |
| Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer (NCT02226276) | City of Hope Medical Center | 2015-01-07 |
| Phase II Study of Everolimus Beyond Progression (NCT02269670) | Emory University | 2014-11-25 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (NCT02273752) | Emory University | 2014-11-01 |
| Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus (NCT02015559) | Jonsson Comprehensive Cancer Center | 2014-10-08 |
| Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung (NCT01741597) | City of Hope Medical Center | 2014-07-01 |
| BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx (NCT02038010) | Northwestern University | 2014-05-21 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer (NCT01938833) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-04-01 |
| Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery (NCT01953588) | Alliance for Clinical Trials in Oncology | 2014-02-27 |
| Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca (NCT02041429) | Dana-Farber Cancer Institute | 2014-02-01 |
| PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer (NCT01712815) | University of Southern California | 2013-11-22 |
| Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT02046421) | University of Chicago | 2013-11-01 |
| Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer (NCT01986569) | Asan Medical Center | 2013-11-01 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection (NCT01249443) | AIDS Malignancy Consortium | 2013-11-01 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (NCT01881230) | Celgene | 2013-09-26 |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer (NCT01918306) | Vanderbilt-Ingram Cancer Center | 2013-09-01 |
| Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer (NCT01873833) | University of Southern California | 2013-07-29 |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (NCT01730833) | City of Hope Medical Center | 2013-07-17 |
| Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer (NCT01868503) | Stanford University | 2013-07-01 |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis (NCT01783756) | Jonsson Comprehensive Cancer Center | 2013-06-26 |
| A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) (NCT01824836) | ECOG-ACRIN Cancer Research Group | 2013-06-11 |
| Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer (NCT01876238) | Case Comprehensive Cancer Center | 2013-05-01 |
| BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (NCT01791478) | Vanderbilt-Ingram Cancer Center | 2013-04-01 |
| Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy (NCT01819233) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-03-08 |
| Cabergoline in Metastatic Breast Cancer (NCT01730729) | Northwestern University | 2013-02-11 |
| A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases (NCT01939483) | University of California, Irvine | 2012-12-01 |
| Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer (NCT01729884) | University of Washington | 2012-12-01 |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy (NCT01720602) | University of Washington | 2012-11-01 |
| Phase I: At-Home Support for Rural Women Using Group Video Calling (NCT01672684) | Stanford University | 2012-10-01 |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery (NCT01705340) | National Cancer Institute (NCI) | 2012-09-01 |
| Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery (NCT01483196) | Wake Forest University Health Sciences | 2012-01-01 |
| BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer (NCT01339442) | Washington University School of Medicine | 2011-11-14 |
| Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole (NCT01478477) | Ohio State University Comprehensive Cancer Center | 2011-10-04 |
| Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases (NCT01421017) | NYU Langone Health | 2011-08-19 |
| Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer (NCT01394211) | University of Arizona | 2011-07-13 |
| Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer (NCT01355393) | University of Washington | 2011-07-01 |
| Circulating miRNAs. (NCT01722851) | Cancer Trials Ireland | 2011-05-01 |
| A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer (NCT01351597) | Korean Breast Cancer Study Group | 2011-04-01 |
| Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer (NCT00992602) | University of Washington | 2011-04-01 |
| Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer (NCT01385280) | University of Arizona | 2011-02-01 |
| Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer (NCT01729832) | Ohio State University Comprehensive Cancer Center | 2011-01-10 |
| Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer (NCT01288261) | University of Arizona | 2011-01-01 |
| Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery (NCT01292083) | University of Southern California | 2011-01-01 |
| Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients. (NCT01276054) | University of Southern California | 2010-12-01 |
| Cryotherapy in Preventing Peripheral Neuropathy and Nail Toxicity in Patients With Breast Cancer Who Are Receiving Paclitaxel (NCT01243541) | Northwestern University | 2010-11-03 |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy (NCT01153672) | University of Washington | 2010-11-01 |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer (NCT01245205) | National Cancer Institute (NCI) | 2010-11-01 |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (NCT01233505) | National Cancer Institute (NCI) | 2010-10-01 |
| Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (NCT01764789) | Ohio State University Comprehensive Cancer Center | 2010-10-01 |
| A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (NCT01147484) | NCIC Clinical Trials Group | 2010-09-02 |
| Endoscopic Breast Surgery in Treating Patients With Breast Cancer (NCT01222377) | University of Southern California | 2010-09-01 |
| Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer (NCT01104259) | University of Washington | 2010-07-01 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors (NCT01155258) | University of Southern California | 2010-06-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer (NCT01151449) | National Cancer Institute (NCI) | 2010-06-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer (NCT01084057) | City of Hope Medical Center | 2010-05-17 |
| Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer (NCT01009983) | Wake Forest University Health Sciences | 2010-03-01 |
| Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer (NCT01051401) | Wake Forest University Health Sciences | 2010-01-01 |
| Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer (NCT01042535) | H. Lee Moffitt Cancer Center and Research Institute | 2009-12-28 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain (NCT01013337) | Abramson Cancer Center at Penn Medicine | 2009-05-01 |
| A Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients With Taxane-Pretreated Recurrent Breast Cancer (NCT00912639) | Korean Breast Cancer Study Group | 2009-05-01 |
| Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer (NCT00821964) | University of Washington | 2008-12-01 |
| Vaccine Therapy in Treating Patients With Stage IV Breast Cancer (NCT00791037) | University of Washington | 2008-10-01 |
| F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer (NCT00602043) | National Cancer Institute (NCI) | 2008-09-01 |
| Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer (NCT00733408) | University of Washington | 2008-04-23 |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (NCT00618657) | University of California, Irvine | 2008-02-01 |
| Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery (NCT00559507) | National Cancer Institute (NCI) | 2007-10-01 |
| Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer (NCT00577122) | Indiana University | 2007-07-01 |
| Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer (NCT00509587) | National Cancer Institute (NCI) | 2007-06-01 |
| VEGF Trap in Treating Patients With Metastatic Breast Cancer (NCT00369655) | National Cancer Institute (NCI) | 2007-01-01 |
| Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer (NCT00416715) | University of Washington | 2006-10-01 |
| AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery (NCT00348699) | National Cancer Institute (NCI) | 2006-07-01 |
| Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1) (NCT00307229) | Ontario Clinical Oncology Group (OCOG) | 2006-03-01 |
| Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer (NCT00331552) | University of Washington | 2006-02-01 |
| Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer (NCT00182767) | National Cancer Institute (NCI) | 2006-01-01 |
| ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment (NCT00425672) | University of Washington | 2005-09-01 |
| A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) (NCT00244881) | National Cancer Institute (NCI) | 2005-09-01 |
| Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer (NCT00096109) | National Cancer Institute (NCI) | 2005-09-01 |
| Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer (NCT00217399) | National Cancer Institute (NCI) | 2005-06-01 |
| Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer (NCT00077376) | National Cancer Institute (NCI) | 2005-03-01 |
| FR901228 in Treating Patients With Metastatic Breast Cancer (NCT00098397) | National Cancer Institute (NCI) | 2005-02-01 |
| 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer (NCT00095888) | National Cancer Institute (NCI) | 2004-10-01 |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases (NCT00098605) | National Cancer Institute (NCI) | 2004-10-01 |
| Sorafenib in Treating Patients With Metastatic Breast Cancer (NCT00096434) | National Cancer Institute (NCI) | 2004-09-01 |
| Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer (NCT00077363) | National Cancer Institute (NCI) | 2004-05-01 |
| Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer (NCT00082810) | National Cancer Institute (NCI) | 2004-03-01 |
| Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer (NCT00079326) | National Cancer Institute (NCI) | 2004-01-01 |
| GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer (NCT00068588) | National Cancer Institute (NCI) | 2003-10-01 |